Salubris

Shenzhen Salubris Pharmaceuticals Co., Ltd. (hereinafter referred to as "Salubris") was established in 1998 and listed on the Shenzhen Stock Exchange in 2009 (Stock Code: 002294). It is an innovation-driven pharmaceutical enterprise based in China, with a global perspective, integrating research, production, and marketing. Salubris adheres to the sacred mission of "providing excellent pharmaceutical products for human health," with its core competitiveness rooted in high-quality innovative products and evidence-based medical promotion, striving to become a leading enterprise in the chronic disease field, primarily focusing on cardiovascular and cerebrovascular diseases. Salubris has undertaken more than 60 major national, provincial, and municipal scientific and technological projects, including those from China's "Eleventh Five-Year Plan," "Twelfth Five-Year Plan," and "Thirteenth Five-Year Plan." It has won the "China Patent Gold Award" three times and has been honored with titles such as "National Technological Innovation Demonstration Enterprise" and "Best Industrial Enterprise in China's Pharmaceutical R&D Product Line."